- Home
- / Delta-Fly Pharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Delta-Fly Pharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
¥533
2024-10-29
Market Capitalization
¥4.5 B
2024-10-29
CreditSafe Score
?
Score changed on Jun 07, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| JPY | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 150.0M | 100.0M | 300.0M | 300.0M | ||||
| Cost of goods sold | (1.5M) | (1.6M) | ||||||
| Gross profit | 150.0M | 100.0M | 300.0M | 300.0M | 1.5M | 1.6M | ||
| Gross profit margin, % | 100.0% | 100.0% | 100.0% | 100.0% | ||||
| Operating expense total | 394.8M | 591.5M | 1.6B | 1.2B | 1.3B | 1.3B | 1.4B | 1.7B |
| Depreciation and amortization | 948.0K | 1.0M | 1.8M | 2.0M | 1.7M | 1.6M | 1.5M | 1.6M |
| EBITDA | (244.8M) | (591.5M) | (1.5B) | (850.2M) | (959.8M) | (1.3B) | (1.4B) | (1.7B) |
| EBITDA margin, % | -163.2% | -1543.8% | -283.4% | -319.9% | ||||
| EBIT | (246.8M) | (671.7M) | (1.5B) | (856.3M) | (963.3M) | (1.3B) | (1.4B) | (1.7B) |
| EBIT margin, % | -164.5% | -1546.1% | -285.4% | -321.1% | ||||
| Interest income | 222.0K | 283.0K | 650.0K | 227.0K | 70.0K | 13.0K | 14.0K | 337.0K |
| Interest expense | 442.0K | 312.0K | 170.0K | 43.0K | ||||
| Pre tax profit | (246.4M) | (671.2M) | (1.6B) | (859.4M) | (964.1M) | (1.3B) | (1.4B) | (1.7B) |
| Income tax expense | 1.8M | 2.5M | 3.6M | 3.2M | 3.2M | 3.0M | 2.5M | 2.5M |
| Net Income | (248.2M) | (673.8M) | (1.6B) | (862.6M) | (967.3M) | (1.3B) | (1.4B) | (1.7B) |